CLINICAL TRIALS PROFILE FOR LANREOTIDE ACETATE
✉ Email this page to a colleague
All Clinical Trials for LANREOTIDE ACETATE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02075606 ↗ | Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients | Completed | Ipsen | Phase 4 | 2014-05-01 | Circulating tumour cells (CTCs) are detectable in the blood in around 50% of patients with functioning NeuroEndocrine Tumours (NET) arising in the midgut area (tumours which are secreting hormones and are located in the area in the middle of the digestive system) and their presence usually means that the prognosis for the patient is poor. CTCs have also been shown to be valuable as predictive markers following treatment and there is increasing interest in using CTCs as 'liquid biopsies' that can help to inform treatment decisions. CTC analysis has the benefit of being relatively non- invasive and quick compared with a conventional CT scan and is therefore an attractive method of monitoring the tumour throughout the treatment period. The purpose of this study is to assess the clinical value that enumeration will have in predicting the clinical symptomatic response and progression free survival in patients receiving Somatuline Autogel for functioning midgut NETs over a one year period. |
| NCT02396953 ↗ | Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly | Completed | Ipsen | Phase 1/Phase 2 | 2015-03-01 | The objectives of the protocol is to determine the maximum tolerated dose and to investigate the pharmacokinetics of a single dose of lanreotide PRF in subjects with acromegaly. |
| NCT02493517 ↗ | Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly | Completed | Ipsen | Phase 3 | 2014-10-01 | The purpose is to compare the efficacy and safety of lanreotide autogel® 60mg, 90mg or 120mg with lanreotide 40mg PR in subjects with active acromegaly. |
| NCT05364944 ↗ | A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) | Not yet recruiting | Debiopharm International SA | Phase 1 | 2022-05-01 | This is an open-label, single treatment arm, multicenter study to assess the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of Debio 4126 in the treatment of participants with Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine tumors (GEP-NETs). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for LANREOTIDE ACETATE
Condition Name
Clinical Trial Locations for LANREOTIDE ACETATE
Clinical Trial Progress for LANREOTIDE ACETATE
Clinical Trial Phase
Clinical Trial Sponsors for LANREOTIDE ACETATE
Sponsor Name
